Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer 2014 Jun;61(6):1126-8 PMID: 24391118 PMCID: PMC4080799

Pubmed ID

24391118

DOI

10.1002/pbc.24918

Abstract

We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic relapse rather than transplant toxicity is the most important cause of treatment failure. Advancements in leukemia control are especially needed for improvement in HCT outcomes for DS-ALL.

Author List

Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA, CIBMTR Pediatric Cancer Working Committee

Authors

Bruce M. Camitta MD Clinical Professor in the Medicine department at Medical College of Wisconsin
Mary Eapen MBBS, DCh, MRCPI, MS Professor in the Medicine department at Medical College of Wisconsin
Mei-Jie Zhang PhD Professor in the Institute for Health and Equity department at Medical College of Wisconsin




Scopus

2-s2.0-84898801407   9 Citations

MESH terms used to index this publication - Major topics in bold

Adolescent
Adult
Allografts
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow Transplantation
Child
Child, Preschool
Combined Modality Therapy
Cyclosporine
Disease-Free Survival
Down Syndrome
Genetic Predisposition to Disease
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Immunosuppressive Agents
Infant
Kaplan-Meier Estimate
Living Donors
Myeloablative Agonists
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Registries
Remission Induction
Retrospective Studies
Salvage Therapy
Tacrolimus
Transplantation Conditioning
Treatment Outcome
Whole-Body Irradiation
jenkins-FCD Prod-353 9ccd8489072cb19f5b9f808bb23ed672c582f41e